Senti Biosciences Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a corporate governance change occurring on September 23, 2026. The filing was signed on September 24, 2026. Senti Biosciences Holdings, Inc. is an emerging growth company whose common stock trades on the Nasdaq Capital Market under the symbol SNTI.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Brenda Cooperstone, Ph.D. resigned from the Company’s Board of Directors effective immediately on September 23, 2026.
- Dr. Cooperstone also resigned as a member and Chair of the Board’s Compensation Committee, effective immediately.
- The filing states that her resignation was not due to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, contingencies, or new business risks. The principal reported item is the immediate departure of the Compensation Committee Chair, which may affect Board committee composition and oversight until a successor or replacement arrangement is disclosed.
Important Facts to Verify
- Whether the Board appoints a replacement director or Compensation Committee Chair.
- Whether the Company discloses any changes to committee membership, compensation oversight, or governance responsibilities.
- Whether subsequent filings identify additional Board or executive changes.